New hope for rare eye cancer: experimental drug extends survival?
Disease control
Completed
This phase 2 trial tested a new drug called IMCgp100 in 378 adults with a specific genetic type (HLA-A*0201) of advanced uveal melanoma, a rare eye cancer. Participants received either IMCgp100 or one of three standard treatments (dacarbazine, ipilimumab, or pembrolizumab). The m…
Phase: PHASE2 • Sponsor: Immunocore Ltd • Aim: Disease control
Last updated May 15, 2026 11:54 UTC